Registry study demonstrates high concordance between an 11-gene PCR panel and standard genomic assays in lung cancer, suggesting a rapid, accessible alternative to next-generation sequencing.
Introduction: The increasing number of actionable alterations across multiple genes in NSCLC has led to the need for molecular testing. Next-generation sequencing is one solution, but the turnaround time and cost limit its use. We assessed the concordance of a Pan Lung Cancer PCR Panel covering 167 variants across 11 genes in NSCLC with validated assays. Methods: fusions) and sufficient residual material were selected from archival samples in the LC-SCRUM-Asia registry. Samples were analyzed by an independent central laboratory blinded to other test results. Results: (Oncomine Comprehensive Assay 3.0), 100%. Conclusions: The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: